1. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
- Author
-
Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, and Cottin V
- Subjects
- Autoantibodies chemistry, Autoimmune Diseases therapy, Autoimmunity, Connective Tissue Diseases immunology, Europe, Humans, Idiopathic Interstitial Pneumonias immunology, Lung Diseases, Interstitial immunology, Prospective Studies, Societies, Medical, United States, Autoimmune Diseases diagnosis, Idiopathic Interstitial Pneumonias diagnosis, Idiopathic Interstitial Pneumonias therapy, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial therapy, Pulmonary Medicine standards
- Abstract
Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest an underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). Researchers have proposed differing criteria and terms to describe these patients, and lack of consensus over nomenclature and classification limits the ability to conduct prospective studies of a uniform cohort.The "European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease" was formed to create consensus regarding the nomenclature and classification criteria for patients with IIP and features of autoimmunity.The task force proposes the term "interstitial pneumonia with autoimmune features" (IPAF) and offers classification criteria organised around the presence of a combination of features from three domains: a clinical domain consisting of specific extra-thoracic features, a serologic domain consisting of specific autoantibodies, and a morphologic domain consisting of specific chest imaging, histopathologic or pulmonary physiologic features.A designation of IPAF should be used to identify individuals with IIP and features suggestive of, but not definitive for, a CTD. With IPAF, a sound platform has been provided from which to launch the requisite future research investigations of a more uniform cohort., (Copyright ©ERS 2015.)
- Published
- 2015
- Full Text
- View/download PDF